|  |  |
| --- | --- |
|  | FULL PAPER |

DOI: 10.1002/adsc.201((will be filled in by the editorial staff))

Expanding the Scope of the Organocatalytic Addition of Fluorobis(phenylsulfonyl)methane to Enals:Enantioselective Cascade Synthesis of Fluoroindane and Fluorochromanol Derivatives

Young Sug Kima,b,†, Sun Min Kima,b,†, Bing Wanga,c, Xavier Companyóa, Jing Lic, Albert Moyanoa, Seoyoung Imd, Zdeněk Tošnere, Jung Woon Yangb\*, Ramon Riosa,e,f\*

a Department de Química Orgànica, Universitat de Barcelona, MartíiFranqués 1-11 08028 Barcelona, Spain

b Department of Energy Science, Sungkyunkwan University, Suwon 440-746, Korea. E-mail: jwyang@skku.edu

c State Key Laboratory of Elemento-Organic Chemistry, College of Chemistry, Nankai University Tianjin, P.R.China, 30007.

d Department of Chemistry, Sungkyunkwan University, Suwon 440-746, Korea

e Laboratory of NMR Spectroscopy, Charles University in Prague, Faculty of Science, Albertov 6, 128 43 Praha 2, Czech Republic

f School of Chemistry, University of Southampton, Southampton, SO17 1BJ, UK. E-mail: R.Rios-Torres@southampton.ac.uk

† These authors contributed equally to this work

Received: ((will be filled in by the editorial staff))

Supporting information for this article is available on the WWW under http://dx.doi.org/10.1002/adsc.201######.((Please delete if not appropriate))

|  |  |
| --- | --- |
| **Abstract.** Highly enantioselective cascade reactions for the synthesis of fluoroindanes and chromanols derivatives are described. The cascade reactions consisted of either a double Michael reaction or Michael-hemiacetal formation via the addition of fluorobis(phenylsulfonyl)methane(FBSM) to enals. The final products were obtained in good yields with excellent stereoselectivities. | **Keywords:** fluorine; Michael; indane; enantioselective; organocatalysis |

Introduction

Since the rediscovery of proline as a catalyst for aldol reactions by List, Barbas, and Lerner in 2000[1] and the subsequent development of iminium catalysis by D. W. C. MacMillan,[2] organocatalysis has emerged as a powerful tool in organic synthesis.[3]

Over the past few years, several research groups have worked to develop new and powerful methodologies for syntheses of complex molecules in high yield with excellent enantioselectivity in a metal-free environment. Moreover, combining two or more organocatalytic reactions into a single protocol has been introduced as a challenging goal to alleviate the need for costly protecting groups and time-consuming purification procedures with individual reaction steps. To address these issues, tandem, domino, cascade, or multicomponent one-pot organocatalytic reactions have been utilized for the efficient diastereo- and enantioselective construction of complex molecules from readily available precursors via simple synthetic routes.[4] For example, a variety of tandem organocatalytic reactions for cyclopropanation [5] and aziridination,[6] as well as Michael-aldol,[7] Michael-Michael,[8] and Michael--alkylation reactions [9] have been developed with excellent results.

The success of fluorination to improve molecular properties has been convincingly demonstrated in a wide range of applications. In many cases, the small, highly electronegative fluorine atom is introduced following a particular rationale, based on our understanding of the effects of fluorination.[10] In the area of life sciences, well-known effects that include enhancement of metabolic stability, conformational stabilisation, and modifications of reactive functional groups give rise to enhanced central nervous system (CNS) penetration or lipophilicity. Importantly, these effects cannot be considered individually as usually a number of molecular properties are influenced simultaneously.[11] For example, fluorination of an amines containing compound to increase its metabolic stability leads to a decrease in p*K*a(H) and an increase its lipophilicity, and thus, may induce strong conformational effects. For this reason, the development of new enantioselective methodologies that can deliver fluorinated compounds, a common moiety in drug candidates, would be of great interest not only for academia but also for the chemical industry.

In the realm of organocatalysis, several methodologies to access fluorine compounds have been developed such as -fluorination[12] or -trifluoromethylation of aldehydes.[13] In 2009, Rios, Wang, and Córdova independently developed an organocatalytic formal β-fluoromethylation of enals catalyzed by secondary amines with fluorobis(phenylsulfonyl)methane (FBSM),[14] resulting in the formation of fluorinated aldehydes with excellent results (Scheme 1).[15]



**Scheme 1.** Formal fluoromethylation was reported in 2009.

Intrigued by the highly enantioselective synthesis of fluorine compounds[16] and encouraged by our previous experience in the synthesis of fluorine compounds[17] and organocatalytic domino reactions,[18] we envisioned an organocatalytic domino reaction that would extend the synthetic applicability of our previously developed FBSM addition to enals.

Results and Discussion

First, we focused on the development of a new Michael-Michael domino process, extending the synthetic utility of FBSM addition to enals.



**Scheme 2.** Proposed catalytic cycle

Taking into account the underlying mechanism of this addition (Scheme 2), we realized that several synthetic protocols could be possible if the generated enamine intermediate **6** (via conjugated addition of FBSM to the α,β-unsaturated iminium ion) attacked an appropriate electrophile. Indane core would result from the domino Michael-Michael reaction sequence via the strategy shown in Scheme 2.

To determine the feasibility of this cascade process, we initially examined the efficacy of chiral organocatalysts **I**-**III** for the addition of FBSM **2** to enal-enone **1a** in toluene at room temperature. The results are summarized in Table 1.

**Table 1.** Screening of reaction parameters[a]



|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Entry | F source | Catalyst | Solvent | Yield(%)[b] | d.r.[c] | Ee(%)[d] |
| 1 | **2** | **I** | toluene | C.M. | - | - |
| 2 | **2** | **II** | toluene | 0 | - | - |
| 3 | **2** | **III** | toluene | 95 | >20:1 | >99 |
| 4 | **2** | **III** | CH2Cl2 | 80 | >20:1 | >99 |
| 5 | **2** | **III** | MeOH | 0 | - | - |
| 6 | **3** | **III** | toluene | C.M. | - | - |

[a] General reaction conditions: **1a** (0.3 mmol), **2**or **3** (0.25 mmol), catalyst **I**-**III** (20 mol%), benzoic acid as additive (20 mol%), solvent (2.0 mL), RT. [b] Determined by 1H NMR of the crude mixture. [c] Determined by 1H NMR of the crude mixture. [d] Determined by chiral-phase HPLC analysis. C.M. = complicated mixture, Conv. = conversion

Among the chiral pyrrolidine catalysts **I-III**, proline gave a complicated mixture (Table 1; entry 1), and no reaction occurred when diarylprolinol TMS ether **II** was employed as the organocatalyst (Table 1; entry 2). Gratifyingly, diphenylprolinol TMS ether **III** significantly increased both the chemical yield and enantioselectivity of the desired product (Table 1; entry 3). To improve the catalytic activity, the reaction conditions were further optimized by examining the solvent and the fluorinating agent. Switching the solvent from toluene to CH2Cl2 or MeOH gave the desired products in 80% and 0% yields, respectively (Table 1; entries 4-5). Treatment with 2-fluoro-1,3-benzodithiole-1,1,3,3-tetraoxide **3**[19] as the fluorinating agent with enal-enone **1a** under the optimized conditions generated a complicated mixture (Table 1; entry 6).

After identifying suitable conditions for the Michael-Michael cyclization, we next explored the scope of this transformation, and the results are shown in Table 2. A variety of aromatic α,β-unsaturated aldehydes with different tethered Michael acceptors, including α,β-unsaturated ketone (Table 2; entries 1-3) and ester, were well tolerated in the intramolecular Michael-Michael cascade reaction. Extremely high levels of diastereoselectivity (>20:1) and enantioselectivity (99% ee) were obtained when enones were used (Table 2, entries 1-4), regardless of the nature of the substituents on the aromatic rings. Substrates bearing an unsaturated ester as electron withdrawing group gave somewhat lower diastereo- and enantioselectivities were obtained (Table 2; entries 5 and 6).

**Table 2.** Reaction Scope[a]



|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Entry | R | Product | X | Yield(%)[b] | d.r.[c] | Ee(%)[d] |
| 1 | - | **4a** | Me | 65 | >20:1 | >99 |
| 2 | 3-F | **4b** | Me | 69 | >20:1 | >99 |
| 3 | 4-MeO | **4c** | Me | 58 | >20:1 | >99 |
| 4 | 3-F | **4d** | Ph | 57 | >20:1 | >99 |
| 5 | - | **4e** | OEt | 65 | 5:1 | 94 |
| 6 | 3-F | **4f** | OEt | 75 | 5:1 | 94 |

[a] General reaction conditions: **1** (0.3 mmol), **2** (0.25 mmol), catalyst **III** (20 mol%), benzoic acid as additive (20 mol%), solvent (2 mL), RT. [b] 1H NMR of the crude mixture. [c] Determined by chiral-phase HPLC analysis.

Stereochemical assignment of adduct **4a** was made on the basis of a uniform reaction mechanism and specific NMR spectroscopy experiments (see Supporting Information).



**Figure 1.** Relative configuration ascertained by nOe experiments

The Michael-Michael tandem reaction led to tri-substituted indane derivative **4**, which featured a *trans*,*trans* substitution pattern (Figure 1).[20]

We have demonstrated that reductive desulfonylation of **4a** could be achieved with Mg-MeOH-NiBr2 system to deliver fluorinated compound **5a** in 71% yield (Scheme 3).



**Scheme 3.** Desulfonylation of **4a**

Next, we decided to study a related Michael-hemiacetal formation cascade reaction for the synthesis of fluorochromanol derivatives. Kim[21] and Wang[22] have recently reported the use of *o*-hydroxycinnamaldehydes as suitable starting materials for easy access to chiral chromanols via an iminium-catalyzed Michael addition, followed by intramolecular hemiacetal formation. Kim demonstrated the nucleophilic addition of malonates, nitroalkanes, and boronic acids to *o*-hydroxycinnamaldehydes **8** with excellent results.

A proposed catalytic cycle for the Michael-hemiacetal formation cascade reaction of *o*-hydroxycinnamaldehyde **8** and FBSM **2** with chiral organocatalyst **III**, similar to the mechanism suggested by the Kim group, is shown in Scheme 4.

The sequencing reaction begins with the activation of the cinnamaldehyde by the organocatalyst to form iminium ion **9**. Subsequently, the iminium ion quickly reacts with FBSM through a 1,4-addition pathway to give enamine intermediate **11**. After deprotonation of the hydroxyl group of *o*-hydroxycinnamaldehyde by the resulting enamine species **11** and subsequent hydrolysis, cyclization provides the chroman-2-ol **13** and regenerates the organocatalyst. An important possible side product in this type of reaction, as previously reported by Wang, is the generation of aminal **10** from iminium ion **9** through the addition of hydroxyl group to α,β-unsaturated iminium ion, thereby trapping the organocatalyst and decreasing the rate of the desired reaction.

We screened different reaction conditions in order to optimize the yield of the reaction and to avoid the formation of **10** (see Supporting Information). To our delight, when *o*-hydroxycinnamaldehyde **8** was treated with FBSM **2** in the presence of catalyst **III** with benzoic acid as an additive in toluene at room temperature, the desired fluorinated chromanol **13** was produced in moderate to good yield and with excellent enantioselectivity.



**Scheme 4.** Proposed catalytic cycle for the Michael-hemiacetal formation cascade reaction

To explore the substrate scope of this transformation, various *o*-hydroxycinnamaldehydes were examined (Table 3). The reaction proceeded well with electron-withdrawing substituent (Table 3; entry 4), electron-donating substituents (Table 3; entry 5) or with different halogen substituents (Table 3; entries 2, 3, 6-9). The desired products **15** were obtained in moderate to good yields (50-75%) with excellent enantioselectivities (92-96% ee) and good diastereo-selectivities, regardless of the electronic nature and sites of substituents on the aromatic ring. A slight decrease in enantioselectivity (89% ee) was observed with 3,5-dichloro-cinnamaldehyde as the substrate.

**Table 3.** Reaction Scope[a]



|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Entry | R | Product | Yield (%)[b] | d.r.[c] | Ee (%)[d] |
| 1 | - | **15a** | 75 | 4:1 | 92 |
| 2 | 5-Cl | **15b** | 67 | 5:1 | 92 |
| 3 | 5-Br | **15c** | 63 | 4:1 | 93 |
| 4 | 5-NO2 | **15d** | 56 | 7:1 | 94 |
| 5 | 5-Me | **15e** | 66 | 3:1 | 96 |
| 6 | 3-Br | **15f** | 65 | 4:1 | 94 |
| 7 | 4-Br | **15g** | 50 | 5:1 | 95 |
| 8 | 3,5-Dichloro | **15h** | 55 | 7:1 | 89 |
| 9 | 3,5-Dibromo | **15i** | 71 | 6:1 | 95 |

[a] General reaction conditions: **14** (0.25 mmol), **2** (0.25 mmol), catalyst **III** (20 mol%), benzoic acid as additive (20 mol%), solvent (1 mL), RT. [b] Determined by 1H NMR of the crude mixture. [c] Determined by chiral-phase HPLC analysis.

Moreover, we expanded this protocol for large-scale preparation of compound **15a**. The reaction of *o*-hydroxycinnamaldehyde was repeated on a 1 g (6.75 mmol) scale [27 times larger than the experiments described in Table 3], giving the product **15a** in 71% yield without any loss of enantioselectivity (92% ee) and diastereomeric ratio (4:1 d.r.) (see Supporting Information).

As a brief demonstration of the utility of the developed methodology, we performed a simple oxidation of hemi-acetal **15a** with PCC to furnish the corresponding lactone **16a** in 84% yield. Next, we proceed to eliminate the 1,1’-bis(sulfone) moiety by reductive desulfonylation with Mg-MeOH-NiBr2 system, which further reductively ring-opened to give the fluorinated product **17a** in 67% yield (Scheme 5).



**Scheme 5.** Derivatization of **15a**

In order to elucidate the absolute configuration of compound **16a**, an X-ray diffraction analysis was performed, shown in Figure 2. From the X-ray structure of **16a**, the single stereogenic centre was unambiguously established as the (*R*)-configuration. The use of the (*S*)-configured catalyst **III** leads to the expected configuration of the product based on the proposed mechanism outlined in Scheme 4.



**Figure 2.** ORTEP drawing of compound **16a**[23]

Conclusion

In summary, we have developed new cascade reactions for the synthesis of indanes and chromanols. Excellent stereoselectivities and moderate to good yields were observed in the addition of FBSM to enals via the Michael-Michael cascade reaction to afford indanes, as well as in the Michael-hemiacetal formation cascade reaction to afford chromanols. Importantly, these cascade reactions provide access to fluoro-substituted indane or chromanol derivatives in a one-pot process.

Experimental Section

General Procedure for the Michael/Michael cascade reaction: In a vial, catalyst **III** (16 mg, 0.05 mmol), fluorobis(phenylsulfonyl)methane **2** (79 mg, 0.25 mmol), and benzoic acid (6.1 mg, 0.05 mmol) were added in 2 mL of toluene to a vial. Next, substrate **1** (0.30 mmol, 1.2 equiv.) was added and the reaction was stirred at room temperature over 3 days. The crude product was purified by column chromatography on silica gel eluting with hexanes/ethyl acetate to afford the final compound **4**.

**(1*S*,2*R*,3*R*)-1-[Fluorobis(phenylsulfonyl)methyl]-3-(2-oxopropyl)-2,3-dihydro-1*H*-indene-2-carbaldehyde (4a)** (65% yield, 83 mg, dark yellow solid) [α]D25 = -194 (*c* 0.5, CHCl3, 96% ee); 1H NMR (400 MHz, CDCl3) δ 10.18 (br, 1H), 7.93 (m, 2H), 7.73 (m, 1H), 7.63 (m, 5H), 7.73 (m, 1H), 7.43 (m, 2H), 7.73 (m, 1H), 7.22 (m, 1H), 7.14 (m, 1H), 7.00 (m, 2H), 4.89 (m, 1H), 4.30 (m, 1H), 3.76 (m, 1H), 3.59 (m, 1H), 3.18 (m, 1H), 2.30 (s, 3H) ppm; 13C NMR (100 MHz, CDCl3) δ 208.1, 200.0, 171.1, 143.9, 137.4, 135.3, 134.8, 131.4, 131.4, 130.7, 128.9, 128.5, 127.3, 124.0, 114.4, 110.8, 60.3, 55.2, 55.2, 50.1, 46.2, 46.1, 41.9, 30.9 ppm; 19F NMR (376 MHz, CDCl3) δ -130.44 ppm; HRMS (ESI) calcd. for C26H27FNO6S2 (M+NH4)+ 532.1264, found 532.1252; Enantiomeric excess: 99%, determined by HPLC (Daicel Chiralpak IA, i-PrOH/Hexane = 10/90), UV 220 nm, flow rate 1 mL/min, major 35.7 min, minor 57.5 min

 **(1*R*,2*R*,3*S*)-5-Fluoro-3-[fluorobis(phenylsulfonyl) methyl]-1-(2-oxopropyl)-2,3-dihydro-1*H*-indene-2-carbaldehyde** **(4b)** (69% yield, 92 mg, yellow foam) [α]D25 = -216 (*c* 0.5, CHCl3, 96% ee); 1H NMR (400 MHz, CDCl3) δ 10.15 (br, 1H), 7.91-7.26 (m, 1H), 7.01 (m, 1H), 6.83 (m, 1H), 6.69 (m, 1H), 4.83 (m, 1H), 4.31 (m, 1H), 3.76 (m, 1H), 3.59 (m, 1H), 3.10 (m, 1H), 2.31 (s, 3H) ppm; 13C NMR (100 MHz, CDCl3) δ 207.7, 199.7, 187.1, 136.1, 135.4, 134.9, 134.5, 131.4, 130.6, 128.9, 128.6, 114.8, 114.6, 111.1, 110.9, 55.8, 55.7, 49.8, 45.7, 45.5, 41.7, 30.2 ppm; 19F NMR (376 MHz, CDCl3) δ -113.68，-130.75 ppm; HRMS (ESI) calcd. for C26H26F2NO6S2 (M+NH4)+ 550.1170, found 550.1155; Enantiomeric excess: 99%, determined by HPLC (Daicel Chiralpak IA, i-PrOH/Hexane = 10/90), UV 220 nm, flow rate 1 mL/min, major 28.9 min, minor 46.4 min.

 **(1*S*,2*R*,3*R*)-1-[Fluorobis(phenylsulfonyl)methyl]-5-methoxy-3-(2-oxopropyl)-2,3-dihydro-1*H*-indene-2-carbaldehyde** **(4c)** (58% yield, 79 mg, yellow foam) [α]D25 = -173 (*c* 0.5, CHCl3, 96% ee); 1H NMR (400 MHz, CDCl3) δ 10.15 (br, 1H), 7.92 (m, 2H), 7.73 (m, 1H), 7.60 (m, 5H), 7.43 (m, 2H), 6.91 (m, 1H), 6.64 (m, 1H), 6.52 (m, 1H), 4.83 (m, 1H), 4.28 (m, 1H), 3.76 (s, 3H), 3.59 (m, 1H), 3.53 (m, 1H), 3.17 (m, 1H), 2.31 (s, 3H) ppm; 13C NMR (100 MHz, CDCl3) δ 208.0, 200.0, 160.2, 145.6, 135.2, 134.7, 131.4, 131.4, 130.6, 130.5, 128.8, 128.5, 126.9, 126.8, 113.9, 108.7, 55.8, 55.7, 55.3, 49.9, 45.8, 45.6, 41.8, 30.3 ppm; 19F NMR (376 MHz, CDCl3) δ -130.18 ppm; HRMS (ESI) calcd. for C27H29FNO7S2 (M+NH4)+ 562.1364, found 562.1372; Enantiomeric excess: 99%, determined by HPLC (Daicel Chiralpak IA, i-PrOH/Hexane = 10/90), UV 220 nm, flow rate 1 mL/min, major 40.1 min, minor 50.9 min.

 **(1*R*,2*R*,3*S*)-5-Fluoro-3-[fluorobis(phenylsulfonyl) methyl]-1-(2-oxo-2-phenylethyl)-2,3-dihydro-1*H*-indene-2-carbaldehyde (4d)** (57% yield, 85 mg, yellow foam) [α]D25 = -190 (*c* 0.4, CHCl3, 99% ee); 1H NMR (400 MHz, CDCl3) δ 10.27 (br, 1H), 8.07-8.04 (m, 2H), 7.92-7.88 (m, 2H), 7.80-7.45 (m, 11H), 7.12-7.05 (m, 1H), 6.90 (dd, *J*1 = 2.3, *J*2 = 8.7 Hz, 1H), 6.74 (td, *J*1 = 8.6, *J*2 = 2.3 Hz, 1H), 4.89 (t, *J* = 6.4 Hz, 1H), 4.40 (t, *J* = 5.0 Hz, 1H), 4.17 (dd, *J*1 = 18.5, *J*2= 9.9 Hz, 1H), 4.01-3.96 (m, 1H), 3.62 (dd, *J*1 = 18.5, *J*2 = 3.9 Hz, 1H) ppm; 13C NMR (100 MHz, CDCl3) δ 199.9, 199.1, 164.6, 137.5, 136.6, 135.4, 135.0, 133.5, 131.5, 131.4, 130.7, 130.7, 129.0, 128.7, 128.6, 128.2, 114.8, 114.6, 111.3, 111.1, 56.1 (d, *J*C-F = 6.1 Hz), 45.8 (d, *J*C-F = 17.2 Hz), 45.3, 42.1 (d, *J*C-F = 1.9 Hz) ppm; 19F NMR (376 MHz, CDCl3) δ -112.6 (m, 1F) -130.3 (s, 1F) ppm; HRMS (ESI) calcd. for C31H28F2NO6S2 (M+NH4)+ 612.6834, found 612.6827; Enantiomeric excess: 99%, determined by HPLC (Daicel Chiralpak IB, i-PrOH/Hexane = 10/90), UV 220 nm, flow rate 1 mL/min, major 24.5 min, minor 39.4 min.

**Ethyl 2-[(1*R*,2*R*,3*S*)-3-(fluorobis(phenylsulfonyl) methyl]-2-formyl-2,3-dihydro-1*H*-inden-1-yl)acetate** **(4e)** (65% yield, 88 mg, yellow scum) [α]D25 = -134 (*c* 0.5, CHCl3, 94% ee); 1H NMR (400 MHz, CDCl3) δ 10.12 (m, 1H), 7.76-7.70 (m, 2H), 7.99-7.93 (m, 2H), 7.84-7.71 (m, 2H), 7.63-7.58 (m, 2H), 7.53-7.48 (m, 2H), 7.08-7.03 (m, 1H), 7.01-6.97 (m, 1H), 6.74-6.68 (m, 1H), , 5.15-5.10 (m, 1H), 5.0-4.95 (m, 1H), 4.85-4.75 (m, 1H), 4.47-4.40 (m, 2H), 3.08 (dd, *J*1 = 17.2, *J*2 = 5.2 Hz, 1H), 2.92 (dd, *J*1 = 17.2, *J*2 = 8.7 Hz, 1H) 1.48 (t, *J* = 7.2 Hz, 3H) ppm; 13C NMR (100 MHz, CDCl3) δ 200.7, 171.5, 147.2, 135.7, 135.3, 134.6, 131.5, 131.4, 130.1, 130.0, 130.0, 129.4, 128.8, 128.5, 114.8, 114.5, 110.6, 110.4, 61.1, 52.1 (d, *J*C-F = 6.5 Hz), 46.4 (d, *J*C-F = 17.8 Hz), 42.9 (d, *J*C-F = 2.3 Hz), 35.3, 14.1 ppm; 19F NMR (376 MHz, CDCl3) δ -113.2 (m), 129.5 (d, *J*H-F = 9.9 Hz) ppm; HRMS (ESI) calcd. for C27H25F2O7S2 (M+H)+ 563.1004, found 563.1009; Enantiomeric excess: 99%, determined by HPLC (Daicel Chiralpak IA, i-PrOH/Hexane = 10/90), UV 220 nm, flow rate 1 mL/min, minor 27 min, major 35 min

**Ethyl 2-[(1*R*,2*R*,3*S*)-5-fluoro-3-(fluorobis (phenylsulfonyl)methyl]-2-formyl-2,3-dihydro-1*H*-inden-1-yl)acetate** **(4f)** (75% yield, 105 mg, white scum) [α]D25= -142 (*c* 0.5, CHCl3, 94% ee); 1H NMR (400 MHz, CDCl3) δ 10.12 (m, 1H), 7.96-7.92 (m, 2H), 7.76-7.70 (m, 2H), 7.62-7.54 (m, 4H), 7.42-7.32 (m, 2H), 7.24-6.90 (m, 4H), 4.94-4.90 (m, 1H), 4.46-4.42 (m, 1H), 3.80 (s, 3H), 3.79-3.70 (m, 1H), 3.34 (dd, *J*­1 = 17.3, *J*2 = 10.7 Hz, 1H), 3.05 (dd, *J*1 = 17.3, *J*2 = 4.1 Hz, 1H) ppm; 13C NMR (100 MHz, CDCl3) δ 199.9, 173.2, 143.6, 137.4, 135.3, 134.8, 131.4, 131.4, 130.7, 128.9, 128.5, 127.3, 124.0, 117.0, 114.4, 55.4 (d, *J*C-F = 6.1 Hz), 51.9, 46.4 (d, *J*C-F = 16.9 Hz), 43.0, 40.1 ppm; 19F NMR (376 MHz, CDCl3) δ -129.2 (d, *J*H-F = 10 Hz) ppm; HRMS(ESI) calcd. for C26H24FO7S2 (M+NH4)+ 531.0942, found 531.0945; Enantiomeric excess: 94%, determined by HPLC (Daicel Chiralpak IA, i-PrOH/Hexane = 10/90), UV 220 nm, flow rate 1 mL/min, major 27 min, minor 34 min.

Procedure for the desulfonylation of **4a**: To a well stirred solution of aldehyde (120 mg, 0.23 mmol) in anhydrous MeOH (5 mL), Mg turning (195 mg, 8.1 mmol) and catalytic amount of NiBr2 were added at 0 oC under Ar atmosphere. After 12 h, the reaction mixture was filtered through Celite. The residue was washed thoroughly with MeOH. The filtrates were pooled, and the liquid was concentrated under reduced pressure. The resulting residue was dissolved in EtOAc, washed with saturated NH4Cl solution, dried over anhydrous Na2SO4, and filtered. The filtrate was concentrated under reduced pressure to a residue, which was purified by column chromatography on silica gel using a gradient eluent system (hexanes/ethyl acetate = 8:1 to 5:1).

**(1*S*,2*S*,3*S*)-5-Fluoro-3-(fluoromethyl)-1-(2-oxopropyl)-2,3-dihydro-1*H*-indene-2-carbaldehyde** **(5a)** (71% yield, 38 mg, brownish liquid) [α]D25 = -16.20 (*c* 1.0, CHCl3); 1H NMR (700 MHz, CDCl3) δ 9.95 (s, 1H), 7.28-7.12 (m, 4H), 4.70 (d, *J* = 4.9 Hz, 1H), 4.64 (d, *J* = 4.9 Hz, 1H), 3.97-3.82 (m, 2H), 3.12-3.06 (m, 1H), 2.83-2.78 (m, 2H), 2.23 (s, 3H) ppm; 13C NMR (175 MHz, CDCl3) δ 207.34, 201.34, 143.87, 139.96 (d, *J* = 5.25 Hz), 128.09, 127.76, 124.25, 123.89, 85.05 (d, *J* = 171.5 Hz), 60.13 (d, *J* = 1.75 Hz), 49.64, 45.43 (d, *J* = 19.25 Hz), 39.92, 29.98 (d, *J* = 92.56 Hz) ppm; 19F NMR (376 MHz, CDCl3) δ -21.87 (td, *J*1 = 94, *J*2 = 23.03 Hz,) ppm; HRMS (ESI+) calcd. for [M+H]+ C14H15O2F: 234.1056, found: 234.1272

General Procedure for the Michael/hemiacetal formation cascade reaction: In a vial, catalyst **III** (16 mg, 0.05 mmol), fluorobis(phenylsulfonyl)methane **2** (79 mg, 0.25 mmol), and benzoic acid (6.1 mg, 0.05 mmol) were added in 1 mL of toluene. Next, substrate **14** (0.25 mmol, 1.0 equiv.) was added and the reaction was stirred at room temperature over 3 days. The crude product was purified by column chromatography on silica gel eluting with hexanes/ethyl acetate to afford the final compound **15**.

**(4*S*)-4-[Fluorobis(phenylsulfonyl)methyl]chroman-2-ol** **(15a)** (75% yield, 87 mg, white solid) [α]D25 **=** +21.16 (*c* 0.5, CHCl3, 93% ee); 1H NMR (400 MHz, CDCl3) δ 8.10-8.06 (m, 2H), 7.78-7.73 (m, 1H), 7.65-7.55 (m, 2H), 7.50-7.30 (m, 2H), 7.25-7.15 (m, 2H), 7.04-6.96 (m, 1H), 6.90-6.75 (m, 2H), 6.36 (t, *J* = 7.6 Hz, 1H), 5.84 (q, *J* = 3 Hz, 1H), 4.50-4.40 (m, 1H), 3.25-3.15 (m, 1H), 2.82-2.76 (m, 1 H) ppm; 13C NMR (100 MHz, CDCl3) δ 152.4, 135.0, 134.4, 131.6, 131.6, 130.1 128.6 128.5, 121.5, 121.0, 118.4, 118.3, 116.9, 116.9, 90.4, 34.2 (d, *J*C-F = 14.9 Hz), 27.5 (d, *J*C-F = 6.9 Hz) ppm; 19F NMR (376 MHz, CDCl3) δ -127.0 (d, *J*H-F = 13.9 Hz) ppm; HRMS (ESI) calcd.for C22H20FO6S2 (M+H)+ 463.0680, found 463.0672;Enantiomeric excess: 93%, determined by HPLC (Daicel Chiralpak IA, i-PrOH/Hexane = 10/90), UV 220 nm, flow rate 1 mL/min, major 28 min, minor 34 min.

**(4*S*)-6-Chloro-4-[fluorobis(phenylsulfonyl) methyl]chroman-2-ol** (**15b**) (67% yield, 83 mg, pale yellow solid) [α]D25 $[α]\_{D}^{20}$**=** +31.16 (*c* 0.5, CHl3, 94% ee); 1H NMR (500 MHz, CDCl3) δ 8.1-8.14 (m, 2H), 7.74-7.8 (m, 1H), 7.6-7.65 (m, 2H), 7.51 (tt, *J*1 = 7.5, *J*2 = 1.5 Hz, 1H), 7.3-7.35 (m, 2H), 7.24-7.27 (m, 1H), 7.19-7.24 (m, 1H), 6.93 (dd, *J*1 = 9, *J*2 = 3 Hz, 1H), 6.74 (broad s, 1H), 6.72 (d, *J*=8.5 Hz, 1H), 5.83-5.87 (m, 1H), 4.39-4.47 (m, 1H), 3.19-3.26 (m, 1H), 2.96 (broad s, 1H), 2.82 (dddd, *J*1 = 14, *J*2 = 7.5, *J*3 = 3, *J*4 = 1 Hz, 1H) ppm; 13C NMR (125 MHz, CDCl3) δ 151.3, 136.8, 136.2, 135.4, 135.2, 132.0, 130.0, 129.7, 129.4 129.3, 128.9, 128.8 (d, *J*C-F = 4.3 Hz), 126.0, 119.8, 118.9, 90.6, 34.1(d, *J*C-F = 14.9 Hz), 27.3(d, *J*C-F = 6.6 Hz) ppm; 19F NMR (470 MHz, CDCl3) δ –127.17 (d, *J*H-F = 22.1 Hz) ppm; HRMS (FAB+) calcd.for C26H27ClFNO6S2 496.0218, found 496.0217; Enantiomeric excess: 92%, determined by HPLC (Daicel Chiralpak IA, i-PrOH/Hexane = 15/85), UV 220 nm, flow rate 1 mL/min, major 22 min, minor 27 min.

 **(4*S*)-6-Bromo-4-[fluorobis(phenylsulfonyl) methyl]chroman-2-ol** (**15c**) (63% yield, 85 mg, pale yellow solid) [α]D25 **=** +35.24 (*c* 0.5, CHCl3, 92% ee); 1H NMR (500 MHz, CDCl3) δ 8.09-8.12 (m, 2H), 7.74-7.79 (m, 1H), 7.6-7.64 (m, 2H), 7.52 (tt, *J*1 = 7.5, *J*2 = 1.5 Hz, 1H), 7.29-7.34 (m, 2H), 7.23-7.28 (m, 1H), 7.2-7.22 (m, 1H), 7.06 (d, *J*1 = 9, *J*2 = 3 Hz, 1H), 6.88 (broad s, 1H), 6.67 (d, *J* = 9 Hz, 1H), 5.82-5.87 (m, 1H), 4.38-4.47 (m, 1H), 3.28 (broad s, 1H), 3.17-3.25 (m, 1H), 2.81 (dddd, *J*1 = 14, *J*2 = 7.5, *J*3 = 3, *J*4 = 1 Hz, 1H) ppm; 13C NMR (125 MHz, CDCl3) δ 151.9, 136.7, 136.1, 135.4, 135.3, 132.3, 132.2, 131.9, 129.9, 128.9, 120.3, 119.4, 113.6, 90.6, 34.1 (d, *J*C-F = 14.9 Hz), 27.3 (d, *J*C-F = 6.8 Hz) ppm; 19F NMR(470 MHz, CDCl3) δ –127.08 (d, *J*H-F = 22.1 Hz) ppm; HRMS (ESI) calcd.for C22H18BrFNO6S2 (FAB+) 541.9692, found 541.9692; Enantiomeric excess: 92%, determined by HPLC (Daicel Chiralpak IA, i-PrOH/Hexane = 15/85), UV 220 nm, flow rate 1 mL/min, major 24 min, minor 28 min.

**(4*S*)-4-[Fluorobis(phenylsulfonyl)methyl]-6-nitrochroman-2-ol** (**15d**) (56% yield, 71 mg, pale yellow solid) [α]D25 **=** +46.68 (*c* 0.5, CHCl3, 94% ee); 1H NMR (500 MHz, CDCl3) δ 8.11 (d, *J* = 8.5 Hz, 2H), 7.83-7.86 (dd, *J*1 = 9, *J*2 = 2.5 Hz, 1H), 7.79 (t, *J* = 7.5 Hz, 1H), 7.71-7.76 (m, 1H), 7.61-7.66 (m, 2H), 7.44 (t, *J* = 7.5 Hz, 1H), 7.32-7.37 (m, 2H), 7.17-7.24 (m, 2H), 6.88 (d, *J* = 9 Hz, 1H), 5.95 (broad s, 1H), 4.47-4.57 (m, 1H), 3.16-3.26 (m, 1H), 2.89-2.97 (m, 1H) ppm; 13C NMR (125 MHz, CDCl3) δ 159.5, 140.8, 136.7, 136.4, 135.9, 135.7, 131.9, 130.1, 130, 126.2, 126.1, 125.6, 119.6, 118.0, 91.3, 34.5 (d, *J*C-F = 15.3 Hz), 28.0 (d, *J*C-F = 6.8 Hz) ppm; 19F NMR (470 MHz, CDCl3) δ –127.66 (d, *J*H-F = 20.7 Hz) ppm; HRMS (ESI) calcd.for C22H18FNO8S2 (M+Na)+ 530.0356, found 530.0356; Enantiomeric excess: 92%, determined by HPLC (Daicel Chiralpak IA, i-PrOH/Hexane = 15/85), UV 220 nm, flow rate 1 mL/min, major 28 min, minor 36 min.

 **(4*S*)-4-[Fluorobis(phenylsulfonyl)methyl]-6-methylchroman-2-ol** (**15e**) (66% yield, 79 mg, dark yellow solid) [α]D25 **=** +25.16 (*c* 0.5, CHCl3, 93% ee); 1H NMR (500 MHz, CDCl3) δ 8.1-8.14 (m, 2H), 7.73-7.78 (m, 1H), 7.58-7.63 (m, 2H), 7.43 (tt, *J*1 = 7.5, *J*2 = 1.5 Hz, 1H), 7.24-7.28 (m, 2H), 7.15-7.2 (m, 2H), ), 6.75-6.79 (m, 1H), 6.68 (d, *J* = 8.5 Hz, 1H), 6.54 (broad s, 1H), 5.81 (q, *J* = 3 Hz, 1H), 4.37-4.47 (m, 1H), 3.21-3.29 (m, 1H), 2.77 (dddd, *J*1 = 14, *J*2 = 7.5, *J*3 = 3, *J*4 = 1 Hz, 1H), 1.79 (s, 3H) ppm; 13C NMR (125 MHz, CDCl3) δ 145.8, 132.5, 131.8, 130.5, 129.7, 127.2, 125.6, 125.5, 125.4, 125.3, 125.1, 124.0, 123.8, 113.6, 112.0, 85.9, 29.7 (d, *J*C-F = 14.8 Hz). 23.0 (d, *J*C-F = 6.9 Hz), 15.9 ppm; 19F NMR (470 MHz, CDCl3) δ –127.74 (d, *J*H-F = 23.5 Hz) ppm; HRMS (ESI) calcd. for C23H21FO6S2 (FAB+) 476.0764, found 476.0764; Enantiomeric excess: 92%, determined by HPLC (Daicel Chiralpak IA, i-PrOH/Hexane = 15/85), UV 220 nm, flow rate 1 mL/min, major 31 min, minor 38 min.

**(4*S*)-8-Bromo-4-[fluorobis(phenylsulfonyl)methyl] chroman-2-ol** (**15f**) (65% yield, 88 mg, pale yellow solid) [α]D25 **=** -74.40 (*c* 0.5, CHCl3, 94% ee); 1H NMR (500 MHz, CDCl3) δ 8.03-8.08 (m, 2H), 7.72-7.77 (m, 2H), 7.56-7.61 (m, 3H), 7.48 (tt, *J*1 = 7.5, *J*2 = 1 Hz, 1H), 7.37-7.41 (m, 2H), 7.27-7.29 (m, 1H), 7.21-7.26 (m, 2H), 6.9-6.93 (m, 1H), 6.28 (t, *J =* 8 Hz, 1H), 5.91 (q, *J* = 3 Hz, 1H), 4.43-4.51 (m, 1H), 3.13-3.2 (m, 1H), 2.77 (ddd, *J*1 = 14.25, *J*2 = 7.75, *J*3 = 2.5 Hz, 1H) ppm; 13C NMR (125 MHz, CDCl3) δ 149.4, 136.9, 136.1, 135.8, 135.3, 134.8, 132.9, 131.7, 130.3, 130.2, 129.6, 128.8 (d, *J*C-F = 6.9 Hz), 121.6, 119.3, 112.6, 91.3, 34.5 (d, *J*C-F = 15.1Hz), 27.9 (d, *J*C-F = 6.8Hz) ppm; 19F NMR (470 MHz, CDCl3) δ -67.1 ppm; HRMS (ESI) calcd. for C22H18BrFO6S2Na (M+Na)+ 564.9592, found 564.9589; Enantiomeric excess: 94%, determined by HPLC (Daicel Chiralpak IA, i-PrOH/Hexane = 15/85), UV 220 nm, flow rate 1 mL/min, major 20 min, minor 26 min.

**(4*S*)-8-Bromo-4-[fluorobis(phenylsulfonyl)methyl] chroman-2-ol** (**15g**) (50% yield, 67 mg, pale yellow solid) [α]D25 **=** -24.76 (*c* 0.5, CHCl3, 95% ee); 1H NMR (500 MHz, CDCl3) δ 8.07-8.11 (m, 2H), 7.74-7.78 (m, 2H), 7.59-7.64 (m, 2H), 7.55 (tt, *J*1 = 7.5, *J*2 = 1.5 Hz, 1H), 7.3-7.35 (m, 2H), 7.25-7.28 (m, 1H), 7.2-7.24 (m, 1H), 6.93 (d, *J* = 2 Hz, 1H), 6.67 (ddd, *J*1 = 8.5, *J*2 = 2.5, *J*3 = 1 Hz, 1 H), 6.37 (dd, *J*1 = 8.5, *J*2 = 2 Hz, 1H), 5.83 (q, *J* = 3 Hz, 1H), 4.35-4.45 (m, 1H), 3.16-3.24 (m, 2H), 2.79 (dddd, *J*1 = 14, *J*2 = 7.5, *J*3 = 3, *J*4 = 1 Hz, 1H) ppm; 13C NMR (125 MHz, CDCl3) δ 153.5, 137.1, 136.3, 135.8, 135.3, 134.5, 131.8, 130.9, 130.8, 130.3, 130.1, 129.6, 128.9 (d, *J*C-F = 12.3 Hz), 124.2, 122.5, 121.5, 116.3, 90.8, 34.1 (d, *J*C-F = 15.1 Hz), 27.5 (d, *J*C-F = 6.9 Hz) ppm; 19F NMR (470 MHz, CDCl3) δ –66.96 ppm; HRMS (ESI) calcd. for C22H18BrFO6S2Na (M+Na)+ 564.9592, found 564.9589; Enantiomeric excess: 95%, determined by HPLC (Daicel Chiralpak IA, i-PrOH/Hexane = 15/85), UV 220 nm, flow rate 1 mL/min, major 18 min, minor 25 min.

**(4*S*)-6,8-Dichloro-4-[fluorobis(phenylsulfonyl) methyl]chroman-2-ol** (**15h**)(55% yield, 73 mg, white solid) [α]D25 **=** 35.36 (*c* 0.5, CHCl3, 89% ee); 1H NMR (500 MHz, CDCl3) δ 8.08-8.13 (m, 2H), 7.96-8.01 (m, 2H), 7.75-7.8 (m, 1H), 7.59-7.64 (m, 3H), 7.52 (tt, *J*1 = 7.5, *J*2 = 1.5 Hz, 1H), 7.36-7.4 (m, 2H), 7.27-7.33 (m, 2H), 7.05 (d, *J* = 2.5 Hz, 1H), 6.73-6.76 (m, 1H), 5.95 (broad s, 1H), 4.4-4.5 (m, 1H), 3.4 (broad s, 1H), 3.17-3.27 (m, 1H), 2.85 (dddd, *J*1 = 14.25, *J*2 = 7.75, *J*3 = 3, *J*4 = 1 Hz, 1H) ppm; 13C NMR (125 MHz, CDCl3) δ 147.6, 136.8, 136.1, 135.8, 135.5, 135.3, 131.9 (d, *J*C-F = 2 Hz), 130.3, 129.9, 129.6, 129.6, 128.8 (d, *J*C-F = 8.4 Hz), 128 (d, *J*C-F = 12 Hz), 125.7, 124.1, 120.5, 118.2, 116.1, 91.2, 34.3 (d, *J*C-F = 14.9 Hz), 27.35 (d, *J*C-F = 6.4 Hz) ppm; 19F NMR (470 MHz, CDCl3) δ –66.95 ppm; HRMS (ESI) calcd. for C22H17Cl2FO6S2 (FAB+) 529.9828, found 529.9828; Enantiomeric excess: 89%, determined by HPLC (Daicel Chiralpak IA, i-PrOH/Hexane = 15/85), UV 220 nm, flow rate 1 mL/min, major 15 min, minor 19 min.

**(4*S*)-6,8-Dibromo-4-[fluorobis(phenylsulfonyl) methyl]chroman-2-ol** (**15i)** (71% yield, 110 mg, white solid) $[α]\_{D}^{20}$ [α]D25 **=** 33.48 (*c* 0.5, CHCl3, 95% ee); 1H NMR (500 MHz, CDCl3) δ 8.09-8.13 (m, 2H), 7.96-8.01 (t, *J* = 2.5 Hz, 1H), 7.60-7.65 (m, 2H), 7.53 (t, *J* = 7.5 Hz, 1H), 7.29-7.4 (m, 5H), 6.9-6.92 (m, 1H), 5.93-5.98 (m, 1H), 4.41-4.56 (m, 1H), 3.35 (broad s, 1H), 3.2-3.29 (m, 1H), 2.8-2.87 (m, 1H) ppm; 13C NMR (125 MHz, CDCl3) δ 148.9, 136.8, 136.1, 135.5, 135.4, 135.2, 132.1, 131.9, 131.6, 131.5, 130.3, 129.9, 129.6, 128.9, 120.9, 113.5, 113.3, 91.3, 34.3 (d, *J*C-F = 14.8 Hz), 27.4 (d, *J*C-F = 6.1 Hz) ppm; 19F NMR (470 MHz, CDCl3) δ –66.91 ppm; HRMS (ESI) calcd. for C22H17Br2FO6S2 (FAB+) 619.8798, found 619.8797; Enantiomeric excess: 95%, determined by HPLC (Daicel Chiralpak IA, i-PrOH/Hexane = 15/85), UV 220 nm, flow rate 1 mL/min, major 16 min, minor 19 min.

Procedure for the oxidation of **15a**: PCC (323 mg, 1.5 mmol) was added to a well stirred solution of hemi-acetal **15a** (231 mg, 0.5 mmol) in anhydrous CH2Cl2 ­(5 mL, 0.1 M) at room temperature. After 3 h, the reaction mixture was filtered through Celite. The resulting residue was dissolved in CH2Cl2, washed with saturated NH4Cl solution, dried over anhydrous Na2SO4, filtered. The filtrate was concentrated under reduced pressure to a residue, which was purified by column chromatography on silica gel eluting with hexanes/ethyl acetate (4:1) to afford **16a** (193 mg, 84% yield) as a white solid.

**(*S*)-4-[Fluorobis(phenylsulfonyl)methyl]chroman-2-one (16a)**  (84% yield, 193 mg, white solid)$[α]\_{D}^{20}$ [α]D25 = +53.08 (*c* 0.5, CHCl3, 93% ee); 1H NMR (500 MHz, CDCl3) δ 7.8-7.87 (m, 2H), 7.71 (t, *J* = 7.5 Hz, 1H), 7.48-7.54 (m, 5H), 7.27-7.3 (m, 2H), 7.22-7.26 (m, 1H), 7.05-7.08 (m, 1H), 6.96 (dd, *J1* = 8, *J*2 = 1 Hz, 1H ), 6.9 (td, *J1* = 7.5, *J*2 = 1 Hz, 1H), 4.45 (dd, *J1* = 12.5, *J*2 = 9.5 Hz, 1H), 4.01 (d, *J* = 18 Hz), 3.1 (ddd, *J1* = 18, *J*2 = 9.5, *J*2 = 2.5 Hz, 1H) ppm; 13C NMR (125 MHz, CDCl3) δ 164.66, 152.92, 135.66, 135.43, 135.26, 135.03, 131.39 (d, *J* = 3.9 Hz), 131.16 (d, *J* = 2.1 Hz), 130.82, 130.29 (d, *J* = 2.1 Hz), 129.05, 128.77, 124.19, 117.92, 114.79, 37.86 (d, *J* = 18.1 Hz), 29.3 (d, *J* = 7.5 Hz) ppm; 19F NMR (470 MHz, CDCl3) δ -158.37 (td, *J1* = 28.2, *J*2 = 11.84 Hz) ppm; HRMS (EI+) calcd. for C22H18FO6S2 (M+H)+ 460.0451, found 460.0447.

Procedure for the desulfonylation of **16a**: Mg turning (391 mg, 16.2 mmol) and NiBr2 (11.8 mg, 0.054 mmol) were added to a well stirred solution of lactone (250 mg, 0.54 mmol) in anhydrous MeOH (20 ml) at -20 oC under Ar atmosphere. After 1 h, the reaction mixture was filtered through Celite, and the residue was washed thoroughly with MeOH. The filtrates were pooled, and the liquid was concentrated under reduced pressure. The resulting residue was dissolved in EtOAc, washed with saturated NH4Cl solution, dried over anhydrous Na2SO4, filtered. The filtrate was concentrated under reduced pressure to a residue, which was purified by column chromatography on silica gel eluting with hexanes/ethyl acetate (12:1) to give **17a** (77 mg, 67% yield) as a colourless liquid.

**Methyl (*S*)-4-fluoro-3-(2-hydroxyphenyl) butanoate (17a)** (67% yield, 77 mg, colorless liquid)[α]D25 = +27.48 (*c* 0.5, CHCl3, 93% ee); 1H NMR (500 MHz, CDCl3) δ 7.07-7.2 (m, 2H), 6.91 (t, *J* = 7.5 Hz, 1H), 6.86 (d, *J* = 8.0 Hz, 1H), 6.85 (s, 1H), 4.62-4.7 (m, 1H), 4.53-4.61 (m, 1H), 3.76-3.89 (m, 1H), 3.66 (s, 3H), 3.0 (dd, *J*1 = 17, *J*2 = 5, 1H), 2.77 (dd, *J1* = 16.5, *J*2 = 9, 1H) ppm; 13C NMR (125 MHz, CDCl3) δ 174.31, 153.96, 128.63, 128.03, 121.38, 117.39, 86.06, 84.69, 52.3, 36.29 (d, *J* = 4 Hz), 35.86 (d, *J* = 19.5 Hz) ppm; 19F NMR (470 MHz, CDCl3) δ -158.37 (td *J*1 = 28.2, *J*2 = 11.8 Hz) ppm; HRMS (FAB+) calcd. for C11H13FO3Na [M+Na]+ 235.0747, found 235.0746.

Acknowledgements

A.M and R.R thank the Spanish Ministry of Science and Innovation (MICINN) for financial support (Project AYA2009-13920-C02-02). X.C. thanks MICINN for a predoctoral fellowship. B.W. is grateful to the China Scholarship Council for a fellowship. J.W.Y. thanks the NRF Nano·Material Technology Development Program (2012M3A7B4049652) for financial support. This work has been done under the auspices of COST Action CM0905 (ORCA). R.R. thanks financial support from European Regional Development Fund (ERDF) (AI-Chem & InterReg IVb).We would like to thank the comment of the referee that pointed out our attention to determine the relative configuration of compound **4a**.

References

[1] B. List, R. A. Lerner, C. F. Barbas, III, *J. Am. Chem. Soc.* **2000**, *122*, 2395-2396.

[2] K. A. Ahrendt, C. J. Borths, D. W. C. MacMillan, *J. Am. Chem. Soc.* **2000**, *122*, 4243-4244.

[3] a) E. Marqués-López, R. P. Herrera, M. Christmann, *Nat. Prod. Rep.* **2010**, *27*, 1138-1167; b) C. Grondal, M. Jeanty, D. Enders, *Nat. Chem.* **2010**, *2*, 167-178; c) D. Enders, A. A. Narine, *J. Org. Chem.* **2008**, *73*, 7857-7870.

[4] a) A. Moyano, R. Rios, *Chem. Rev.* **2011**, *111*, 4703-4832; b) A.-N. Alba, X. Companyó, M. Viciano, R. Rios, *Curr. Org. Chem.* **2009**, *13*, 1432-1474; c) D. Enders, C. Grondal, M. R. M. Huettl, *Angew. Chem. Int. Ed.* **2007**, *46*, 1570-1581.

[5] a) R. Rios, H. Sundén, J. Vesely, G.-L. Zhao, P. Dziedzic, A. Córdova, *Adv. Synth. Catal.* **2007**, *349*, 1028-1032; b) H. Xie, L. Zu, H. Li, J. Wang, W. Wang, *J. Am. Chem. Soc.* **2007**, *129*, 10886-10894; c) I. Ibrahem, G. L. Zhao, R. Rios, J. Vesely, H. Sundén, P. Dziedzic, A. Córdova, *Chem. Eur. J.* **2008**, *14*, 7867-7879; d) J. Vesely, G.-L. Zhao, A. Bartoszewicz, A. Córdova, *Tetrahedron Lett.* **2008**, *49*, 4209-4212.

[6] a) J. Vesely, I. Ibrahem, G.-L. Zhao, R. Rios, A. Córdova, *Angew. Chem. Int. Ed.* **2007**, *46*, 778-781; b) F. Pesciaioli, V. F. De, P. Galzerano, G. Bencivenni, G. Bartoli, A. Mazzanti, P. Melchiorre, *Angew. Chem. Int. Ed.* **2008**, *47*, 8703-8706.

[7] J. Wang, H. Li, H. Xie, L. Zu, X. Shen, W. Wang, *Angew. Chem. Int. Ed.* **2007**, *46*, 9050-9053.

[8] a) H. Li, L. Zu, H. Xie, J. Wang, W. Jiang, W. Wang, *Org. Lett.* **2007**, *9*, 1833-1835; b) J. W. Yang, M. T. H. Fonseca, B. List, *J. Am. Chem. Soc.* **2005**, *127*, 15036-15037.

[9] D. Enders, C. Wang, J. W. Bats, *Angew. Chem. Int. Ed.* **2008**, *47*, 7539-7542.

[10] a) S. Purser, P. R. Moore, S. Swallow, V. Gouverneur, *Chem. Soc. Rev.* **2008**, *37*, 320-337; b) P. Kirsch, Modern Fluoroorganic Chemistry: Synthesis, Reactivity, Applications, WILEY-VCH, Weinheim, 2004;

[11] a) D. O’Hagan, Chem Soc Rev **2008**, 37, 308-319; b) L. Hunter *Beilstein J. Org. Chem.***2010**, *6*, 38; c) L. E. Zimmer, C. Sparr, R. Gilmour *Angew. Chem. Int. Ed.* **2011**, *50*, 11860-11871.

[12] a) T. D. Beeson, D. W. C. MacMillan, *J. Am. Chem. Soc.***2005**, *127*, 8826-8828; b) D. Enders, M. R. M. Huettl, *Synlett* **2005**, 991-993; c) J. Franzen, M. Marigo, D. Fielenbach, T. C. Wabnitz, A. Kjrsgaard, K. A. Jorgensen, *J. Am. Chem. Soc.* **2005**, *127*, 18296-18297.

[13]A. E. Allen, D. W. C. MacMillan *J. Am. Chem. Soc.* **2010**, *132*, 4986-4987.

[14] For excellent previous works using FBSM: a) T. Fukuzumi, N. Shibata, M. Sugiura, H. Yasui, S. Nakamura, T. Toru, *Angew. Chem. Int. Ed.* **2006**, *45*, 4973-4977; b) C. Ni, Y. Li, J. Hu, *J. Org. Chem.* **2006**, *71*, 6829-6833; c) G. K. S. Prakash, S. Chacko, S. Alconcel, T. Stewart, T. Mathew, G. A. Olah, *Angew. Chem. Int. Ed.* **2007**, *46*, 4933-4936; d) X. Shen, L. Zhang, Y. Zhao, L. Zhu, G. Li, J. Hu, *Angew. Chem. Int. Ed*. **2011**, *50*, 2588-2592; e) G. K. Prakash, J. Hu. *Acc. Chem. Res.* **2007**, 921-930. For an interesting paper regarding 1,2 *vs* 1,4 addition of fluoronucleophiles, see: f) X. Shen, C. Ni, J. Hu, *Helv. Chim. Acta* **2012**, *95*, 2043-2051.

[15] a) A.-N. Alba, X. Companyó,A. Moyano, R. Rios, *Chem. Eur. J.* **2009**, *15*, 7035-7038; b) S. Zhang, Y. Zhang, Y. Ji, H. Li, W. Wang, *Chem. Commun.* **2009**, 4886-4888; c) F. Ullah, G.-L. Zhao, L. Deiana, M. Zhu, P. Dziedzic, I. Ibrahem, P. Hammar, J. Sun, A. Córdova, *Chem. Eur. J.* **2009**, *15*, 10013-10017.

[16] G. Vallero, X. Companyó,R. Rios, *Chem. Eur. J.* **2011**, *17*, 2018-2037.

[17] a) X. Companyó, G. Valero, V. Ceban, T. Calvet, M. Font-Bardia, A. Moyano, R. Rios, *Org. Biomol. Chem.* **2011**, *9*, 7986-7989; b) X. Companyó, M. Hejnová, M. Kamlar, J. Vesely, A. Moyano, R. Rios, *Tetrahedron Lett.***2009**, *50*, 5021-5024; c) M. Kamlar, N. Bravo, A. N. R. Alba, S. Hybelbauerova, I. Cisarova, J. Vesely, A. Moyano, R. Rios, *Eur. J. Org. Chem.* **2010**, 5464-5470.

[18] a) X. Companyó, A. Zea, A.-N. R. Alba, A. Mazzanti, A. Moyano, R. Rios, *Chem. Commun.* **2010**, *46*, 6953-6955; b) A. N. R. Alba, A. Zea, G. Valero, T. Calbet, M. Font-Bardia, A. Mazzanti, A. Moyano, R. Rios, *Eur. J. Org. Chem.* **2011**, 1318-1325; c) G. Valero, J. Schimer, I. Cisarova, J. Vesely, A. Moyano, R. Rios, *Tetrahedron Lett.* **2009**, *50*, 1943-1946.

[19] T. Furukawa, Y. Goto, J. Kawazoe, E. Tokunaga, S. Nakamura, Y. Yang, H. Du, A. Kakehi, M. Shiro, N. Shibata, *Angew. Chem. Int. Ed.* **2010**, *49*, 1642-1647.

[20] A similar reaction was described by Palomo and coworkers for the synthesis of trisubstituted indanes via the addition of methylene sulfone derivatives to enals. A. Landa, A. Puente, J. I. Santos, S. Vera, M. Oiarbide, C. Palomo, *Chem. Eur. J.* **2009**, *15*, 11954-11962.

[21] a) Y. Lee, S. W. Seo, S.-G. Kim, *Adv. Synth. Catal.* **2011**, *353*, 2671-2675; b) K.-S. Choi, S.-G. Kim, *Eur. J. Org. Chem.* **2012**, 1119-1122; c) Y. Lee, S.-G. Kim, *Bull. Korean Chem. Soc.* **2011**, *32*, 311-314.

[22] L. Zu, S. Zhang, H. Xie, W. Wang, *Org. Lett.* **2009**, *11*, 1627-1630.

[23] CCDC-961044 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Center via [www.ccdc.cam.ac.uk/data\_request/cif](http://www.ccdc.cam.ac.uk/data_request/cif).

|  |  |  |  |
| --- | --- | --- | --- |
| FULL PAPER |  |  |  |
| **Expanding the Scope of the Organocatalytic Addition of Fluorobis(phenylsulfonyl)methane to Enals: Enantioselective Cascade Synthesis of Fluoroindane and Fluorochromanol Derivatives** |  |  |
| *Adv. Synth. Catal.***Year**, *Volume*, Page – Page |
| Young Sug Kim, Sun Min Kim, Bing Wang, Xavier Companyó, Jing Li, Albert Moyano, Seoyoung Im, Zdeněk Tošner, Jung Woon Yang\*, Ramon Rios\* |